KR20220074895A - 필요로 하는 대상체의 중독 치료 및/또는 예방을 위한 시티신을 포함하는 조성물 - Google Patents

필요로 하는 대상체의 중독 치료 및/또는 예방을 위한 시티신을 포함하는 조성물 Download PDF

Info

Publication number
KR20220074895A
KR20220074895A KR1020227012082A KR20227012082A KR20220074895A KR 20220074895 A KR20220074895 A KR 20220074895A KR 1020227012082 A KR1020227012082 A KR 1020227012082A KR 20227012082 A KR20227012082 A KR 20227012082A KR 20220074895 A KR20220074895 A KR 20220074895A
Authority
KR
South Korea
Prior art keywords
subject
cytocine
weeks
smoking
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020227012082A
Other languages
English (en)
Korean (ko)
Inventor
신디 에이. 제이콥스
다니엘 에프. 카인
앤소니 클라크
Original Assignee
어치브 라이프 사이언시즈, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 어치브 라이프 사이언시즈, 인크. filed Critical 어치브 라이프 사이언시즈, 인크.
Publication of KR20220074895A publication Critical patent/KR20220074895A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020227012082A 2019-09-12 2020-08-14 필요로 하는 대상체의 중독 치료 및/또는 예방을 위한 시티신을 포함하는 조성물 Ceased KR20220074895A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962899637P 2019-09-12 2019-09-12
US62/899,637 2019-09-12
US202062988890P 2020-03-12 2020-03-12
US62/988,890 2020-03-12
PCT/US2020/046308 WO2021050203A1 (en) 2019-09-12 2020-08-14 Compositions comprising cytisine in the treatment and/or prevention of addiction in subjects in need thereof

Publications (1)

Publication Number Publication Date
KR20220074895A true KR20220074895A (ko) 2022-06-03

Family

ID=74866435

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227012082A Ceased KR20220074895A (ko) 2019-09-12 2020-08-14 필요로 하는 대상체의 중독 치료 및/또는 예방을 위한 시티신을 포함하는 조성물

Country Status (11)

Country Link
US (3) US11083715B2 (https=)
EP (1) EP4027815B1 (https=)
JP (2) JP7742832B2 (https=)
KR (1) KR20220074895A (https=)
CN (4) CN119564619A (https=)
AU (1) AU2020346695A1 (https=)
BR (1) BR112022004519A2 (https=)
CA (1) CA3153405A1 (https=)
MX (1) MX2022002882A (https=)
WO (1) WO2021050203A1 (https=)
ZA (1) ZA202204075B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119564619A (zh) * 2019-09-12 2025-03-07 阿奇维生命科学公司 治疗和/或预防有需要的受试者的成瘾的包括野靛碱的组合物
CA3230630A1 (en) * 2021-09-08 2023-03-16 Curtis SWIFT Analytical methods of assessing cytisine purity
JP2024095092A (ja) * 2022-12-28 2024-07-10 株式会社日立製作所 生成装置、生成方法、および生成プログラム
AU2024263979A1 (en) * 2023-04-26 2025-10-23 Achieve Life Sciences, Inc. Compositions comprising cytisine in the treatment and/or prevention of addiction in subjects in need thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1983002892A1 (fr) 1982-02-22 1983-09-01 Talapin, Vitaly, Ivanovich Preparation medicinale possedant un effet antinicotine et son procede d'obtention
EP0937077B1 (en) * 1996-10-30 2006-05-17 Pfizer Inc. Pyridone-fused azabicyclic- or cytisine derivatives, their preparation and their use in addiction therapy
AR044007A1 (es) * 2003-04-11 2005-08-24 Newron Pharmaceuticals Inc Metodos para el tratamiento de la enfermedad de parkinson
CN102014995B (zh) * 2007-03-30 2015-05-13 菲利普莫里斯生产公司 用于输送药剂的装置和方法
CN103284319A (zh) * 2013-06-20 2013-09-11 昌宁德康生物科技有限公司 一种金雀花碱替代尼古丁口腔雾化液及其制备方法
EP3011026B1 (en) * 2013-06-21 2019-12-18 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating apolipoprotein c-iii expression for improving a diabetic profile
US20160199315A1 (en) * 2013-08-23 2016-07-14 Hisamitsu Pharmaceutical Co., Inc. Adhesive patch
PL409829A1 (pl) * 2014-10-18 2016-04-25 Łukasz Zalewski Płyn z cytyzyną do elektronicznych papierosów
GB201602145D0 (en) * 2016-02-05 2016-03-23 Achieve Pharma Uk Ltd Salt
KR102848174B1 (ko) * 2017-07-24 2025-08-27 어치브 파마 유케이 리미티드 시티신 염
CN119564619A (zh) * 2019-09-12 2025-03-07 阿奇维生命科学公司 治疗和/或预防有需要的受试者的成瘾的包括野靛碱的组合物

Also Published As

Publication number Publication date
EP4027815A4 (en) 2023-06-07
JP2022548876A (ja) 2022-11-22
CN118286217A (zh) 2024-07-05
JP2025081331A (ja) 2025-05-27
US20210077473A1 (en) 2021-03-18
CN119587493A (zh) 2025-03-11
US11083716B2 (en) 2021-08-10
BR112022004519A2 (pt) 2022-05-31
US20210077475A1 (en) 2021-03-18
EP4027815A1 (en) 2022-07-20
AU2020346695A1 (en) 2022-04-28
WO2021050203A1 (en) 2021-03-18
US20210330652A1 (en) 2021-10-28
JP7742832B2 (ja) 2025-09-22
MX2022002882A (es) 2022-05-10
EP4027815B1 (en) 2026-04-15
ZA202204075B (en) 2023-11-29
CN119564619A (zh) 2025-03-07
CN114727647A (zh) 2022-07-08
US11083715B2 (en) 2021-08-10
CA3153405A1 (en) 2021-03-18

Similar Documents

Publication Publication Date Title
Newmeyer et al. Subjective and physiological effects, and expired carbon monoxide concentrations in frequent and occasional cannabis smokers following smoked, vaporized, and oral cannabis administration
Henningfield et al. Pharmacotherapy for Nicotine Dependence 1
Rose et al. Extinguishing the rewarding value of smoke cues: pharmacological and behavioral treatments
Blondal et al. The effects of fluoxetine combined with nicotine inhalers in smoking cessation‐a randomized trial
JP7742832B2 (ja) 嗜癖の治療および／または予防を必要とする対象の嗜癖の治療および／または予防におけるシチシンを含む組成物
Rose et al. Platelet monoamine oxidase, smoking cessation, and tobacco withdrawal symptoms
WO2011020061A2 (en) Compositions and methods of for treating bipolar disorder
US20120225949A1 (en) Compositions and methods for treating bipolar disorder
Hertling et al. Craving and other characteristics of the comorbidity of alcohol and nicotine dependence
Wagen et al. Benefits and risks of pharmacological smoking cessation therapies in chronic obstructive pulmonary disease
Rose et al. Combined effects of nicotine and mecamylamine in attenuating smoking satisfaction.
Miller et al. Cigarette mentholation increases smokers' exhaled carbon monoxide levels.
Albertson et al. The pharmacological approach to the elderly COPD patient
CN121532188A (zh) 包含金雀花碱的组合物用于治疗和/或预防有此需要的受试者的成瘾
van Lemmen et al. Reversal of fentanyl-induced apnea: a randomized comparison between intramuscular (Zimhi) and intranasal naloxone (Narcan)
Penetar et al. Benztropine pretreatment does not affect responses to acute cocaine administration in human volunteers
Guidance Mental Health Clinician Guidance for Managing People’s Smoking Cessation
Glover et al. N icotine R eduction T herapy
Sinclair et al. Evidence-based consensus guidelines for the pharmacological management of substance dependence: Recommendations from the British Association for Psychopharmacology
Wise et al. A review of nonpharmacologic and pharmacologic therapies for smoking cessation.
Cobb Evaluating the acute effects of caffeinated waterpipe tobacco in waterpipe users
Sullivan et al. State of the art reviews: smoking cessation: a review of treatment considerations
Adhikari et al. A Discussion about Modalities of Smoking Cessation in Perioperative Phase for Addicts: A Review Article
Sofuoglu et al. STIMULANTS AND RELATED DRUGS
RENNARD et al. 13 Treatment of Stable COPD

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601